Grand Pharma’s Migraine Prevention TCM Drug Doses First Patient in China Phase II Trial

The significance here lies less in the migraine indication than in the pathway: a hospital preparation moving into formal evidence-based verification is a test case for whether long-standing clinical experience can be converted into approvable, trial-backed assets. It matters for Grand Pharma's TCM pipeline and for the broader class of hospital-origin preparations seeking regulatory legitimacy. The open question is whether Phase II enrollment and eventual readouts validate that translation, and how the company's otolaryngology-focused TCM program progresses from here.